Santhera's idebenone misses in Phase I/II for primary progressive MS

Santhera Pharmaceuticals Holding AG (SIX:SANN) said idebenone (SNT-MC17) missed the primary endpoint in an NIH-sponsored Phase I/II trial to

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE